Patents by Inventor Abran Costales

Abran Costales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10815446
    Abstract: Disclosed is a dispersant composition, suitable for use in lubricating oils. The dispersant composition is a reaction product of (i) a polyalkenyl succinimide post-treated with a post-treating agent selected from the group consisting of an organic carbonate, an epoxide, a lactone, a hydroxyaliphatic carboxylic acid, and combinations thereof; and (ii) an acylating agent.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 27, 2020
    Assignee: CHEVRON ORONITE COMPANY LLC
    Inventors: William Raymond Ruhe, Jr., Georgeta Masson, Abran Costales, Kirk Nass, John Robert Miller, Young A. Chang
  • Publication number: 20180334635
    Abstract: Disclosed is a dispersant composition, suitable for use in lubricating oils. The dispersant composition is a reaction product of (i) a polyalkenyl succinimide post-treated with a post-treating agent selected from the group consisting of an organic carbonate, an epoxide, a lactone, a hydroxyaliphatic carboxylic acid, and combinations thereof; and (ii) an acylating agent.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 22, 2018
    Inventors: William Raymond Ruhe, JR., Georgeta Masson, Abran Costales, Kirk Nass, John Robert Miller, Young A. Chang
  • Publication number: 20130224195
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 29, 2013
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Patent number: 8415382
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Publication number: 20100075965
    Abstract: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.
    Type: Application
    Filed: February 14, 2007
    Publication date: March 25, 2010
    Inventors: Zhi-Jie Ni, Sabina Pecchi, Matthew Burger, Wooseok Han, Aaron Smith, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Joelle Verhagen, Yanchen Zhang, Ed Iwanowicz, Tom Hendrickson, Mark Knapp, Hanne Merritt, Charles Voliva, Marion Wiesmann, Darren Mark Legrand, Ian Bruce, James Dale, Jiong Lan, Barry Levine, Abran Costales, Jui Liu, Teresa Pick, Daniel Menezes
  • Patent number: 7671059
    Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: March 2, 2010
    Assignee: Novartis AG
    Inventors: Timothy D. Machajewski, Cynthia M. Shafer, Christopher McBride, William Antonios-McCrea, Brandon M. Doughan, Barry H. Levine, Yi Xia, Maureen McKenna, X. Michael Wang, Kris Mendenhall, Yasheen Zhou, Kristin Brinner, Zhenhai Gao, Daniel Poon, Paul Barsanti, Xiaodong Lin, Abran Costales, Alice Rico, Nathan Brammeier, Teresa Pick, Paul A. Renhowe
  • Publication number: 20100004237
    Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.
    Type: Application
    Filed: July 31, 2009
    Publication date: January 7, 2010
    Inventors: Timothy D. Machakewski, Cynthia M. Shafer, Christopher McBride, William Antonios-McCrea, Brandon M. Doughan, Barry H. Levine, Yi Xia, Maureen McKenna, X. Michael Wang, Kris Mendenhall, Yasheen Zhou, Baoqing Gong, Dan Gu, John Dolan, John Tulinsky, Kristin Brinner, Zhenhai Gao, Daniel Poon, Paul Barsanti, Xiaodong Lin, Abran Costales, Alice Rico, Nathan Brammeier, Teresa Pick, Paul A. Renhowe
  • Publication number: 20090035309
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 5, 2009
    Inventors: Abran COSTALES, Teresa HANSEN, Barry H. LEVINE, Christopher McBRIDE, Daniel J. POON, Savithri RAMURTHY, Paul A. RENHOWE, Cynthia M. SHAFER, Sharadha SUBRAMANIAN, Joelle VERHAGEN
  • Patent number: 7423150
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: September 9, 2008
    Assignee: Novartis AG
    Inventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
  • Publication number: 20070027150
    Abstract: 2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.
    Type: Application
    Filed: April 14, 2006
    Publication date: February 1, 2007
    Inventors: Cornelia Bellamacina, Abran Costales, Brandon Doughan, Susan Fong, Zhenhai Gao, Thomas Hendrickson, Barry Levine, Xiaodong Lin, Timothy Machajewski, Christopher McBride, William Antonios-McCrea, Maureen McKenna, Kris Mendenhall, Alice Rico, Cynthia Shafer, X. Wang, Yi Xia, Yasheen Zhou
  • Publication number: 20050192287
    Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Application
    Filed: October 15, 2004
    Publication date: September 1, 2005
    Applicant: Chiron Corporation
    Inventors: Abran Costales, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Joelle Verhagen